Equities

Solasia Pharma KK

Solasia Pharma KK

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)27.00
  • Today's Change1.00 / 3.85%
  • Shares traded3.39m
  • 1 Year change-42.55%
  • Beta1.4421
Data delayed at least 20 minutes, as of May 09 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Solasia Pharma K.K. is a Japan-based pharmaceutical company. The Company is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. It focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The Company's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).

  • Revenue in JPY (TTM)617.00m
  • Net income in JPY-1.11bn
  • Incorporated2007
  • Employees24.00
  • Location
    Solasia Pharma KK3F, Shiodome Bldg., 1-2-20, KaiganMINATO-KU 105-0011JapanJPN
  • Phone+81 358438045
  • Fax+81 367212020
  • Websitehttps://solasia.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
D.Western Therapeutics Institute Inc428.36m-812.41m3.45bn21.00--2.69--8.06-25.45-25.4513.4839.830.16070.43892.9820,398,290.00-31.09-13.06-33.75-14.3691.4494.29-193.39-72.5110.57--0.4089---4.407.90-89.07--7.08--
Kringle Pharma Inc70.58m-865.79m3.67bn13.00--1.49--51.96-158.59-158.5912.88374.930.024--0.73085,428,846.00-29.38-19.00-30.70-20.23-----1,226.76-156.5126.45-1,190.330.00---82.33---157.41------
Human Metabolome Technologies Inc1.32bn282.64m3.82bn57.0013.492.1610.462.8947.8347.83223.67299.170.630214.234.7423,186,330.0013.48--16.73--65.03--21.39--4.27151.900.1103--6.21--6.71------
Kubota Pharmaceutical Holdings Co Ltd39.89m-1.49bn3.94bn12.00--1.48--98.80-26.80-26.800.717547.210.01070.531714.773,323,917.00-40.06-36.51-43.86-39.4770.48---3,734.55-13,528.8710.01--0.0512--383.24--26.11--24.38--
Perseus Proteomics Inc96.22m-1.12bn4.01bn24.00--2.47--41.63-95.57-95.578.18131.490.04241.8211.224,009,083.00-49.52-33.51-51.65-34.9589.0193.09-1,168.66-470.6317.58--0.00--30.96-20.89-31.38--228.18--
OncoTherapy Science, Inc.901.22m-1.19bn4.03bn60.00--5.97--4.47-5.77-5.774.363.010.75895.3115.7415,020,330.00-100.44-50.21-132.58-55.41-9.03---132.35-331.973.29-258.180.00---1.6339.9756.50---57.92--
FunPep Co Ltd530.00k-933.42m4.08bn15.00--1.65--7,704.49-40.11-40.110.022594.970.0002----35,333.33-34.04-27.10-35.68-28.75-----176,116.20-815.8225.95-1,765.730.00---50.33-72.8020.39---13.14--
BrightPath Biotherapeutics Co Ltd118.00k-1.21bn4.19bn32.00--4.95--35,470.65-19.27-19.270.001911.920.00007--0.04233,687.50-71.34-42.65-89.42-44.49-433.0557.16-1,028,827.00-4,430.66---875.450.3929---65.73-56.89-0.0971---56.39--
Immuno-Biological Laboratories Co., Ltd.788.12m-192.71m4.45bn60.00--4.05--5.65-20.69-20.6984.62118.020.51440.87883.7813,135,280.00-12.58-15.11-14.85-17.6162.0656.66-24.45-50.043.490.4940.1774--22.710.9405-11.97------
Renascience Inc191.32m-331.66m4.53bn3.00--2.76--23.65-26.09-26.0915.05129.220.0851----63,772,000.00-14.74---15.49--85.75---173.36------0.1782---27.84---32.05------
MEDRx Co Ltd29.53m-932.90m4.98bn22.00--2.37--168.59-27.24-27.240.849250.170.01710.26061.221,342,455.00-54.07-58.15-58.45-62.2391.8795.70-3,158.72-1,526.1717.75--0.00---50.3528.6016.04---55.29--
Solasia Pharma KK617.00m-1.11bn5.03bn24.00--2.41--8.15-6.61-6.613.6710.780.23014.101.9325,708,330.00-41.51-48.57-47.74-58.8354.7871.01-180.39-300.892.91--0.031---43.5014.1856.36------
Kidswell Bio Corp2.62bn-1.21bn5.51bn41.00--3.73--2.11-37.72-37.7277.5637.570.55831.264.0063,807,830.00-25.82-58.77-36.65-77.4450.3059.87-46.25-139.311.86-21.980.6118--76.9221.24-22.83------
KAINOS Laboratories, Inc.4.98bn647.70m5.57bn144.007.890.83327.221.12154.88154.881,192.401,466.620.6052.893.1334,615,160.007.866.6610.259.0751.4151.5212.999.892.53--0.113317.016.692.3310.9015.37-46.2314.87
Cyfuse Biomedical KK61.11m-589.21m5.68bn21.00--1.77--92.87-75.45-75.457.82405.800.01350.54073.982,910,095.00-13.05---15.34--61.76---964.15--5.92-71.550.2218---83.68---24.32------
Delta-Fly Pharma Inc0.00-1.26bn6.00bn11.00--3.55-----187.93-187.930.00205.250.00----0.00-92.45-53.35-103.56-55.60-------769.75---391.170.00---100.00---37.37------
Data as of May 09 2024. Currency figures normalised to Solasia Pharma KK's reporting currency: Japanese Yen JPY

Institutional shareholders

1.65%Per cent of shares held by top holders
HolderShares% Held
Rheos Capital Works, Inc. (Investment Management)as of 30 Sep 20222.32m1.30%
Simplex Asset Management Co., Ltd.as of 04 Apr 2024618.60k0.35%
Data from 31 Mar 2024 - 19 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.